Clinical Trials Logo

Recurrent Islet Cell Carcinoma clinical trials

View clinical trials related to Recurrent Islet Cell Carcinoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02273752 Terminated - Clinical trials for Stage IV Breast Cancer

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Start date: November 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well real-time pharmacokinetic therapeutic drug monitoring works in preventing stomatitis from developing in patients with hormone receptor positive breast cancer, pancreatic neuroendocrine tumors, or kidney cancer that are receiving a type of cancer drug called everolimus. Stomatitis is a common side effect of everolimus that causes inflammation of the mouth, with or without oral ulcers, and frequently leads to patients discontinuing the medication. Monitoring the blood levels of everolimus and making adjustments in a patient's dose may be able to decrease the incidence of stomatitis, while maintaining the effectiveness of everolimus to treat the cancer.

NCT ID: NCT02031536 Terminated - Liver Metastases Clinical Trials

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

Start date: April 10, 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well everolimus works in treating patients with pancreatic neuroendocrine tumors metastatic to the liver previously treated with surgery. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving everolimus after surgery may kill any tumors cells that remain.

NCT ID: NCT00084461 Terminated - Insulinoma Clinical Trials

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Start date: March 2004
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.